The closing price of Guardant Health Inc (NASDAQ: GH) was $17.13 for the day, down -0.70% from the previous closing price of $17.25. In other words, the price has decreased by -$0.12 from its previous closing price. On the day, 1670105 shares were traded. GH stock price reached its highest trading level at $17.35 during the session, while it also had its lowest trading level at $16.95.
Ratios:
Our analysis of GH’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.24 and its Current Ratio is at 6.54. In the meantime, Its Debt-to-Equity ratio is 8.53 whereas as Long-Term Debt/Eq ratio is at 8.36.
Raymond James Upgraded its Mkt Perform to Outperform on November 13, 2023, while the target price for the stock was maintained at $27.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 18 ’24 when Kalia Kumud bought 2,187 shares for $17.82 per share. The transaction valued at 38,963 led to the insider holds 12,722 shares of the business.
Joyce Meghan V. sold 100 shares of GH for $1,905 on Mar 04 ’24. The Director now owns 4,521 shares after completing the transaction at $19.05 per share. On Dec 04 ’23, another insider, Joyce Meghan V., who serves as the Director of the company, sold 100 shares for $26.34 each. As a result, the insider received 2,634 and left with 4,422 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GH now has a Market Capitalization of 2.10B and an Enterprise Value of 2.28B. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.70 while its Price-to-Book (P/B) ratio in mrq is 13.13. Its current Enterprise Value per Revenue stands at 4.05 whereas that against EBITDA is -5.27.
Stock Price History:
Over the past 52 weeks, GH has reached a high of $41.06, while it has fallen to a 52-week low of $17.06. The 50-Day Moving Average of the stock is 20.89, while the 200-Day Moving Average is calculated to be 28.49.
Shares Statistics:
GH traded an average of 1.63M shares per day over the past three months and 1.7M shares per day over the past ten days. A total of 121.63M shares are outstanding, with a floating share count of 115.90M. Insiders hold about 4.78% of the company’s shares, while institutions hold 92.60% stake in the company. Shares short for GH as of Feb 29, 2024 were 7.05M with a Short Ratio of 4.32, compared to 5.54M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.79% and a Short% of Float of 6.04%.
Earnings Estimates
The firm’s stock currently is rated by 18 analysts. On average, analysts expect EPS of -$0.84 for the current quarter, with a high estimate of -$0.66 and a low estimate of -$1.04, while EPS last year was -$1.3. The consensus estimate for the next quarter is -$0.8, with high estimates of -$0.63 and low estimates of -$0.99.
Analysts are recommending an EPS of between -$2.5 and -$3.81 for the fiscal current year, implying an average EPS of -$3.16. EPS for the following year is -$2.86, with 21 analysts recommending between -$1.85 and -$3.48.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 18 analysts. It ranges from a high estimate of $161.9M to a low estimate of $147M. As of the current estimate, Guardant Health Inc’s year-ago sales were $128.71M, an estimated increase of 16.90% from the year-ago figure. For the next quarter, 18 analysts are estimating revenue of $160.99M, an increase of 17.40% over than the figure of $16.90% in the same quarter last year. There is a high estimate of $166.54M for the next quarter, whereas the lowest estimate is $157.2M.
A total of 21 analysts have provided revenue estimates for GH’s current fiscal year. The highest revenue estimate was $676M, while the lowest revenue estimate was $658.6M, resulting in an average revenue estimate of $664.03M. In the same quarter a year ago, actual revenue was $563.95M, up 17.70% from the average estimate. Based on 21 analysts’ estimates, the company’s revenue will be $808.31M in the next fiscal year. The high estimate is $869.9M and the low estimate is $760.6M. The average revenue growth estimate for next year is up 21.70% from the average revenue estimate for this year.
